This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CMC Strategy Forum Fall 2020
Share |

NEW DATES! Due to the current situation with the COVID-19 (also known as coronavirus) outbreak, this forum will now take place virtually October 13-15, 2020. Each session will still include live speaker presentations and panel discussions, and will last approximately 3.5 hours each day. We are incredibly grateful for your support and flexibility during this difficult time.

CMC Strategies and Phase-appropriate GMP Approaches for Expedited Program Development


Nina Cauchon, Amgen Inc.
Carmilia Jiménez-Ramirez, BioMarin Pharmaceutical Inc.
Michael Kennedy, CBER, FDA
Ramesh Potla, CDER, FDA


Natalya Ananyeva, CBER, FDA 
Lucy Chang, Merck & Co., Inc.
Bharat Dixit, ClearB Therapeutics
Narasaiah Dontha, Celgene Corporation, A Bristol-Myers Squibb Company
Michelle Lytle, Eli Lilly and Company
Polly Mak, Genentech, a Member of the Roche Group
David Robbins, AstraZeneca
Karen Rowlandson, Health Canada
Jason Starkey, Pfizer, Inc.

In the first two decades of the 21st century, significant advances have been made in the science of drug development resulting in an array of new modalities entering the clinic. Regulators and sponsors alike are subject to increasing pressures to expedite the availability of these drugs globally for the treatment of unmet medical needs. Beginning with the United States and the European Union, health authorities from many countries have now implemented accelerated regulatory pathways that are based on the potential for significant patient benefit. The clinical successes of these drugs have resulted in significantly reduced development timelines, thus generation of CMC information for marketing authorizations is on the critical path to approval. Additionally, companies face significant challenges when managing post-approval changes globally. Solutions are often worked out on a case-by-case basis between each sponsor and regulatory agency since each program and modality present unique challenges. However, common topics and questions do exist from a CMC perspective. In concert with CMC challenges presented when managing expedited programs, the interpretation of phase-appropriate GMP guidance from health authorities remains a subject open to interpretation from industry experts. Interaction between regulatory agencies and industry representatives can assist with the development of harmonized risk-based approaches and develop tools to address these challenges, thus facilitating a common understanding of CMC challenges, and implementing strategies to ensure phase-appropriate GMP compliance.

This three-day CMC Forum will address pitfalls, risk mitigation levers, and risk-based approaches for common CMC issues, and discuss regulatory tools currently available to accelerate development in various countries. The first and second day of this forum will focus on CMC strategies for expedited program development, while the third day will focus on phase-appropriate GMPs and practical considerations for expedited programs. Specific topics and questions will be discussed via the use of case studies.


Want more information? Check out the "More in this Section" dropdown box at the top of the page!
Or contact CASSS at 510-428-0740 or





more Calendar

9/28/2020 » 10/1/2020
CE Pharm 2020

10/13/2020 » 10/15/2020
CMC Strategy Forum North America Fall 2020

Membership Software Powered by YourMembership  ::  Legal